[1]
M. Tosi, M. Catteruccia, C. Cherchi, I. Mizzoni, and A. D’Amico, “Switching therapies: safety profile of Onasemnogene abeparvovec-xioi in a SMA1 patient previously treated with Risdiplam”, Acta Myol, vol. 41, no. 3, pp. 117–120, Sep. 2022.